NCT01536652已完成不适用
Prandial Oriented NovoMix 30® - the Physiological Insulin Therapy of Diabetes Type 2
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 4,994
- 主要终点
- HbA1c (glycosylated haemoglobin)
研究概览
简要总结
This study is conducted in Europe. The aim of this observational study is to document the glycaemic parameters, adverse events, including drug reactions, as well as hypoglycaemic episodes, in patients that switched from insulin glargine combined with oral antidiabetic drugs (OADs) to biphasic insulin aspart 30 (NovoMix® 30) combined with OADs, when applicable.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with diabetes mellitus type 2
排除标准
- 未提供
研究组 & 干预措施
BIAsp 30 users
干预措施: biphasic insulin aspart 30 (Drug)
结局指标
主要结局
HbA1c (glycosylated haemoglobin)
次要结局
- Insulin dosage
- Incidence of (serious) adverse drug reactions
- Incidence of hypoglycaemic episodes
- Body weight
- Preprandial and postprandial blood glucose values (self measured)
研究者
相似试验
已完成
不适用
Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1NCT00665093Novo Nordisk A/S1,569
已完成
不适用
Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT00729898Novo Nordisk A/S243
撤回
不适用
A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in AlgeriaDiabetes Mellitus, Type 2NCT03862690Novo Nordisk A/S
已完成
4 期
Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADsDiabetesDiabetes Mellitus, Type 2NCT01486862Novo Nordisk A/S26
已完成
不适用
Observational Study of Type 1 and Type 2 Diabetes Patients Having Switched From Human Premixes to NovoMix®30DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2NCT00675493Novo Nordisk A/S942